Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

A month has gone by since the last earnings report for Vertex Pharmaceuticals (VRTX). Shares have lost about 0.8% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

Vertex has built its earnings thanks to its CF program, and with a new CF drug approved a few months ago, the company may be ...

Vertex Pharmaceuticals Inc. closed 14.97% short of its 52-week high of $519.88, which the company achieved on November 8th.

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

Eli Lilly has reached a deal to acquire SiteOne Therapeutics that would give it control of a non-opioid pain drug that would ...

Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion. Analysts surveyed by Visible Alpha were looking for $4.19 and $2.83 billion, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

U.S. equities dropped at midday as the markets awaited any news on tariffs and tomorrow's Federal Reserve decision.

The stock's fall snapped a four-day winning streak.